Pacific Biosciences of California, Inc. provided revenue guidance for the fourth quarter ended December 31, 2022. For the quarter, the company reported unaudited preliminary revenue of approximately $27.3 million for its fourth quarter ended December 31, 2022.
Pacific Biosciences of California, Inc.
Equities
PACB
US69404D1081
Advanced Medical Equipment & Technology
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.045 USD | -5.98% |
|
+56.54% | -79.26% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-79.26% | 592M | |
+4.80% | 212B | |
+8.69% | 187B | |
+26.88% | 155B | |
+33.97% | 115B | |
+2.17% | 65.5B | |
+14.07% | 52.87B | |
-3.30% | 45.25B | |
-3.37% | 39.7B | |
+6.45% | 37.72B |
- Stock Market
- Equities
- PACB Stock
- News Pacific Biosciences of California, Inc.
- Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2022